Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

2,679 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
External validation of hemoglobin and neutrophil levels as predictors of the effectiveness of ipilimumab plus nivolumab for treating renal cell carcinoma.
Hamamoto S, Tasaki Y, Yamashita S, Furukawa J, Fujita K, Tomida R, Miyake M, Ito N, Iwamoto H, Sugiyama Y, Taguchi K, Yasui T. Hamamoto S, et al. Among authors: sugiyama y. Front Oncol. 2024 Sep 2;14:1400041. doi: 10.3389/fonc.2024.1400041. eCollection 2024. Front Oncol. 2024. PMID: 39286026 Free PMC article.
Low Geriatric Nutritional Risk Index as a Poor Prognostic Marker for Second-Line Pembrolizumab Treatment in Patients with Metastatic Urothelial Carcinoma: A Retrospective Multicenter Analysis.
Etani T, Naiki T, Sugiyama Y, Nagai T, Iida K, Noda Y, Shimizu N, Tasaki Y, Mimura Y, Okada T, Banno R, Kubota H, Hamamoto S, Ando R, Kawai N, Yasui T. Etani T, et al. Among authors: sugiyama y. Oncology. 2020;98(12):876-883. doi: 10.1159/000508923. Epub 2020 Aug 28. Oncology. 2020. PMID: 32862183
First Report of Oncological Outcome and Prognostic Analysis in a First-Line Setting of Short Hydration Gemcitabine and Cisplatin Chemotherapy for Patients with Metastatic Urothelial Carcinoma.
Naiki T, Nagai T, Sugiyama Y, Etani T, Nozaki S, Iida K, Noda Y, Shimizu N, Isobe T, Matsumoto D, Kubota H, Hamamoto S, Ando R, Kawai N, Yasui T. Naiki T, et al. Among authors: sugiyama y. Oncology. 2021;99(10):622-631. doi: 10.1159/000517326. Epub 2021 Jul 20. Oncology. 2021. PMID: 34284409
Real-world data on efficacy/safety and economic impact of nivolumab administered every 2 and 4 weeks among Japanese patients.
Tasaki Y, Ito N, Mimura Y, Sugiyama Y, Ogawa R, Shimura T, Nakamura M, Kawakita D, Hamamoto S, Uemura T, Yokota K, Iida M, Odagiri K, Kimura Y, Hotta Y, Komatsu H, Okuda K, Niimi A, Yasui T, Iwasaki S, Morita A, Kataoka H, Takiguchi S, Furukawa-Hibi Y. Tasaki Y, et al. Among authors: sugiyama y. Asia Pac J Clin Oncol. 2024 Aug;20(4):515-521. doi: 10.1111/ajco.14073. Epub 2024 Apr 29. Asia Pac J Clin Oncol. 2024. PMID: 38682421
Pure Lymphoepithelioma-Like Carcinoma Originating from the Urinary Bladder.
Nagai T, Naiki T, Kawai N, Iida K, Etani T, Ando R, Hamamoto S, Sugiyama Y, Okada A, Mizuno K, Umemoto Y, Yasui T. Nagai T, et al. Among authors: sugiyama y. Case Rep Oncol. 2016 Mar 23;9(1):188-94. doi: 10.1159/000445049. eCollection 2016 Jan-Apr. Case Rep Oncol. 2016. PMID: 27099604 Free PMC article.
Chronological transition in outcome of second-line treatment in patients with metastatic urothelial cancer after pembrolizumab approval: a multicenter retrospective analysis.
Isobe T, Naiki T, Sugiyama Y, Naiki-Ito A, Nagai T, Etani T, Nozaki S, Iida K, Noda Y, Shimizu N, Tomiyama N, Banno R, Kubota H, Hamamoto S, Ando R, Kawai N, Yasui T. Isobe T, et al. Among authors: sugiyama y. Int J Clin Oncol. 2022 Jan;27(1):165-174. doi: 10.1007/s10147-021-02046-z. Epub 2021 Oct 11. Int J Clin Oncol. 2022. PMID: 34633579
2,679 results